How many drugs treat Bone Metastases of Solid Tumors?

Drug Landscape tracks 3 marketed treatments for Bone Metastases of Solid Tumors (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bone-metastases-of-solid-tumors.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Bone Metastases of Solid Tumors — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bone Metastases of Solid Tumors (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bone Metastases of Solid Tumors, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zometa	ZOLEDRONIC ACID	Novartis	zoledronic acid	Farnesyl pyrophosphate synthase	2001-01-01
Zometa	Zometa	University of Arkansas		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase
Zoledronate	Zoledronate	Children's Hospital Medical Center, Cincinnati		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Children's Hospital Medical Center, Cincinnati · 1 drug in Bone Metastases of Solid Tumors
Novartis · 1 drug in Bone Metastases of Solid Tumors
University of Arkansas · 1 drug in Bone Metastases of Solid Tumors

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bone Metastases of Solid Tumors:

Cite this brief

Drug Landscape (2026). Bone Metastases of Solid Tumors — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bone-metastases-of-solid-tumors. Accessed 2026-06-11.

Bone Metastases of Solid Tumors full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing